The members of the Beneluxa Initiative have reviewed the Dutch Horizon Scan 2023-2024 of upcoming marketing authorization of medicines. Using selection criteria such as expected therapeutic impact…
The Beneluxa Initiative aims to ensure sustainable access
to innovative medicine at affordable cost for our patients.
The Beneluxa initiative identified four impactful medicines suitable for a joint submission
Beneluxa reaching out to other collaborations: international experience sharing on negotiations of new pharmaceuticals
From the 27th – 28th of June 2022, Amgros and the Nordic Pharmaceutical Forum hosted an international workshop on negotiations on new pharmaceuticals with representatives from organizations in 9…
Ireland, Belgium and the Netherlands complete joint HTA report on gene therapy Libmeldy
The first step in the joint reimbursement process for Libmeldy® (atidarsagene autotemcel), a gene therapy product for the treatment of children with metachromatic leukodystrophy, was successfully…